在切换到基于整合酶抑制剂的疗法后,肝肥胖症并没有与短期体重增加相平行
Alejandro Gonzalez-Serna1,2,3, Juan Macías1,3,4, Pilar Rincon1,3
1Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen de Valme/CSIC/Universidad de Sevilla.
AIDS (London, England)
|October 25, 2023
概括
对于艾滋病毒 (PWH) 感染者来说,切换到基于整合酶抑制剂 (INSTI) 的疗法在一年后没有显著改变肝肥胖症. 在这个队列中观察到的体重增加与肝脏脂肪含量变化无关.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝硬化是艾滋病毒感染者 (PWH) 的一个问题.
- 基于整合酶抑制剂 (INSTI) 的疗法通常用于HIV治疗.
- 在切换到基于INSTI的疗法后,体重增加和肝脂肪变化之间的关系需要进一步研究.
研究的目的:
- 在切换到基于INSTI的治疗方案后,研究PWH中肝肥胖症的变化.
- 评估这个人群中体重增加和肝肥胖症变化之间的相关性.
主要方法:
- 研究了154个PWH的队列.
- 使用控制衰减参数 (CAP) 评估肝肥胖症.
- 体重变化和CAP在基线和48周后被测量.
主要成果:
- 在48周后,中位体重增加为1.2公斤.
- 平均CAP变化为-4dB/m,表明肝硬化症略有下降.
- 体重增加与加农政策变化有很弱,不显著的相关性 (P=0.074).
结论:
- 在PWH治疗一年后,切换到基于INSTI的疗法似乎没有显著影响肝肥胖症.
- 在切换到基于INSTI的疗法后观察到的体重增加与肝硬化症的变化无关.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Hepatic Drug Excretion: Influencing Factors
134
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
134
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
676
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
676
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Hepatic Drug Clearance: Effect of Protein Binding
216
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
216
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
128
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
128


